Related Experiment Video
Updated: Mar 29, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
44.6K
Vascular endothelial dysfunction and pharmacological treatment
1Jin Bo Su, INSERM U955, 94700 Maisons-Alfort, France.
World Journal of Cardiology
|December 5, 2015
Summary
Vascular endothelial dysfunction, linked to cardiovascular diseases, involves impaired nitric oxide (NO) bioavailability. Various drugs show protective effects, but treatment must target specific underlying mechanisms.
Area of Science:
- Cardiovascular Science
- Endothelial Biology
- Pharmacology
Background:
- The endothelium regulates vascular tone, permeability, coagulation, inflammation, and cell growth.
- Endothelial dysfunction arises from risk factors like hypertension, smoking, and aging, impacting vascular health.
- Dysfunction involves impaired vasodilators, enhanced vasoconstrictors, oxidative stress, and inflammation.
Purpose of the Study:
- To review the mechanisms of endothelial dysfunction in cardiovascular diseases.
- To highlight the central role of reduced nitric oxide (NO) bioavailability.
- To discuss the endothelial protective effects of various drugs.
Main Methods:
- Literature review of experimental and clinical studies.
- Analysis of risk factors contributing to endothelial dysfunction.
- Examination of drug mechanisms targeting endothelial dysfunction.
Main Results:
- Endothelial dysfunction is implicated in numerous cardiovascular diseases.
- Reduced nitric oxide (NO) bioavailability is a key factor in endothelial dysfunction.
- Multiple drug classes, including ACE inhibitors and statins, demonstrate endothelial protective effects.
Conclusions:
- Endothelial dysfunction is a critical component of cardiovascular disease pathogenesis.
- Targeting NO bioavailability and other mechanisms is crucial for treatment.
- Pharmacological interventions should be tailored to specific disease mechanisms.
Keywords:
Endothelial dysfunctionEndothelial nitric oxide synthaseEndothelium-dependent vasodilationInflammationNitric oxidePharmacological treatmentReactive nitrogen speciesReactive oxygen speciesRisk factorsMore Related Videos
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
729
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
729
01:26Atherosclerosis III: Management
582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:27Peripheral Artery Disease III: Interprofessional Care
559
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
559
01:24Regulation of Angiogenesis and Blood Supply
4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
01:27Coronary Artery Disease V: Interprofessional Care
398
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398